The Advisory Committee on Immunization Practices voted healthcare workers and residents of long-term care facilities should receive the vaccine first.


LONDON – The United Kingdom became the first western country to approve widespread use of a COVID-19 vaccine developed by drug companies Pfizer and BioNTech, the British government said Wednesday.

The Medicines and Healthcare products Regulatory Agency said the first shots will be given next week. Studies show it is 95% effective.

The move makes Britain one of the first countries to begin vaccinating its population as it tries to curb Europe’s deadliest COVID-19 outbreak.

Other countries aren’t far behind: The U.S. and the European Union also are vetting the Pfizer/BioNTech shot along with a similar vaccine made by competitor Moderna.

China and Russia have already begun a mass rollout of their own coronavirus vaccines. However, they have done so before completing late-stage clinical trials.

The Pfizer/BioNTech vaccine took 10 months to go from concept to distribution. The development of a vaccine typically takes about a decade.

The companies said thy would immediately begin shipping limited supplies to the U.K., which has ordered enough of the vaccine for 20 million people.

They are also gearing up for even wider distribution if given a similar nod by the U.S. Food and Drug Administration. A decision in the U.S. is expected as early as next week.

But doses everywhere are scarce, and initial supplies will be rationed until more is manufactured in the first several months of next year.

Pfizer CEO Albert Bourla called the U.K. decision “a historic moment.”

“We are focusing on moving with the same level of urgency to safely supply a high-quality vaccine around the world,” Bourla said in a statement.

US coronavirus map: Tracking the outbreak

Two doses three weeks apart are required for protection and one of the distribution challenges is that the vaccine must be stored at ultra-cold temperatures.

The U.K. government said frontline health care workers and nursing home residents, followed by older adults, will be prioritized for vaccination.

A vial of the COVID-19 candidate vaccine developed by BioNTech and Pfizer is displayed at the headquarters in Puurs, Belgium. (Photo: AP Images)

British regulators also are considering another shot made by AstraZeneca and Oxford University. But Prime Minister Boris Johnson has warned “we must first navigate a hard winter” of restrictions to try to curb the virus until there’s enough vaccine to go around.

Every country has different rules for determining when an experimental vaccine is safe and effective enough to use. Researchers pledged to cut no corners.

Three promising COVID vaccine candidates: This is what we know about them.

The shots made by U.S.-based Pfizer and its German partner BioNTech were tested in tens of thousands of people. The companies told regulators that of the first 170 infections detected in study volunteers, only eight were among people who’d received the actual vaccine and the rest had gotten a dummy shot.

“This is an extraordinarily strong protection,” Dr. Ugur Sahin, BioNTech’s CEO, recently told The Associated Press.

The companies also reported no serious side effects, although vaccine recipients may experience temporary pain and flu-like reactions immediately after injections.

But experts caution that a vaccine cleared for emergency use is still experimental and the final testing must be completed. Still to be determined is whether the Pfizer-BioNTech shots protect against people spreading the coronavirus without showing symptoms. Another question is how long protection lasts.

The vaccine also has been tested in only a small number of children, none younger than 12, and there’s no information on its effects in pregnant women.


Show Thumbnails

Show Captions

Last SlideNext Slide

Contributing: Associated Press

Read or Share this story: